Market closed
Myriad Genetics/$MYGN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Myriad Genetics
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Ticker
$MYGN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,700
Website
Myriad Genetics Metrics
BasicAdvanced
$1.3B
-
-$1.30
1.94
-
Price and volume
Market cap
$1.3B
Beta
1.94
52-week high
$29.08
52-week low
$12.04
Average daily volume
1.1M
Financial strength
Current ratio
1.9
Quick ratio
1.462
Long term debt to equity
17.712
Total debt to equity
19.557
Interest coverage (TTM)
-31.80%
Management effectiveness
Return on assets (TTM)
-5.35%
Return on equity (TTM)
-16.39%
Valuation
Price to revenue (TTM)
1.582
Price to book
1.81
Price to tangible book (TTM)
9.97
Price to free cash flow (TTM)
-12.141
Growth
Revenue change (TTM)
12.15%
Earnings per share change (TTM)
-61.49%
3-year revenue growth (CAGR)
6.37%
3-year earnings per share growth (CAGR)
20.08%
What the Analysts think about Myriad Genetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Myriad Genetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Myriad Genetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Myriad Genetics News
AllArticlesVideos
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
GlobeNewsWire·1 week ago
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
GlobeNewsWire·2 weeks ago
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Myriad Genetics stock?
Myriad Genetics (MYGN) has a market cap of $1.3B as of February 16, 2025.
What is the P/E ratio for Myriad Genetics stock?
The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of February 16, 2025.
Does Myriad Genetics stock pay dividends?
No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of February 16, 2025.
When is the next Myriad Genetics dividend payment date?
Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Myriad Genetics?
Myriad Genetics (MYGN) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.